Holen Sie sich die Stockscreener-App
1.96
6.67%
-0.14
Vorhandelsmarkt:
1.98
0.02
+1.02%
Schlusskurs vom Vortag:
$2.10
Offen:
$2.1
24-Stunden-Volumen:
1.07M
Relative Volume:
0.52
Marktkapitalisierung:
$311.64M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-29.47M
KGV:
-9.80
EPS:
-0.2
Netto-Cashflow:
$-21.55M
1W Leistung:
-3.92%
1M Leistung:
+10.11%
6M Leistung:
+7.10%
1J Leistung:
-52.43%
1-Tages-Spanne:
$1.96
$2.1066
1-Wochen-Bereich:
$1.92
$2.1066
52-Wochen-Spanne:
$1.47
$4.72
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Firmenname
Mereo Biopharma Group Plc Adr
Sektor
Branche
Telefon
4403330237300
Adresse
ONE CAVENDISH PLACE, LONDON
Vergleichen Sie MREO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.96 | 334.10M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-13 | Fortgesetzt | BTIG Research | Buy |
| 2022-08-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Needham | Buy |
Alle ansehen
Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Rating of "Buy" by Brokerages - MarketBeat
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Adage Capital Partners GP L.L.C. Has $3.83 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Frazier Life Sciences Management L.P. Increases Stock Holdings in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - FinancialContent
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Analysts Set Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Price Target at $7.20 - MarketBeat
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Investors in Mereo BioPharma Group plc (MREO) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Finanzdaten der Mereo Biopharma Group Plc Adr-Aktie (MREO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):